Brain metastases are common in patients with ROS1-positive, advanced NSCLC, having been detected in approximately 40% of cases19, which highlights the need for central nervous system (CNS)-penetrating treatments with proven intracranial efficacy for these patients20,21. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.